About Zumutor Biologics Private Limited
Data last updated: 06 January 2026
Zumutor Biologics Private Limited is a foreign private limited company based in Bangalore, Karnataka, India, a subsidiary of Zumutor Biologics Inc and recognised as a startup by DPIIT. It specialises in biotechnology, a part of the broader life sciences sector. Incorporated on 31 July 2015, the company has been in operation for over 11 years.
Registered with ROC Bangalore under CIN U73200KA2015FTC081944.
Capital: an authorised share capital of ₹1.41 Lakh and a paid-up capital of ₹1.2 Lakh. It is led by directors including Ashwin Raguraman and Maloy Ghosh.
Last AGM: 28 July 2025. Financial statements filed for year ended 31 March 2025. Office: Bangalore, Karnataka.
As per the financials filed for FY 2025, the company reported a revenue of ₹4.63 Cr, a decline of 64% compared to the previous year.
The company has a workforce of approximately 23 employees as per the latest available data. It operates as a subsidiary of Zumutor Biologics Inc.
The company is associated with 1 brand - Zumutor Biologics.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website zumutor.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressPrasad Enclave # 118/119 Ground Floor Yeswantpur Ind Suburb Ii Stage 5Th Mn, Yeswantpur, Bangalore, Karnataka, India – 560022
-
IndustryLife Sciences, Biotechnology
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Zumutor Biologics Private Limited
Zumutor Biologics Private Limited operates one associated brand: Zumutor Biologics. These brands represent Zumutor Biologics Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Zumutor Biologics is focused on developing novel immunotherapies. | zumutor.com |
Competitors & Alternatives of Zumutor Biologics Private Limited
Brands and companies operating in the same space as Zumutor Biologics Private Limited include Moderna, BeiGene, Strand Therapeutics and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Moderna
|
mRNA-based therapeutics for diseases including cancer and infections are developed. | Cambridge, United States, United States | 2010 |
BeiGene
|
Targeted and immune-oncology drugs for cancer treatment are developed. | Cambridge, United States, United States | 2010 |
Strand Therapeutics
|
mRNA therapeutics platform is provided for multi-functional treatments. | Cambridge, United States, United States | 2017 |
Regeneron Pharmaceuticals
|
Antibodies are developed for treating cancer, eye, and inflammatory diseases. | Tarrytown, United States, United States | 1988 |
Annexon
|
Developer of antibodies to treat complement-mediated neurodegenerative diseases | San Francisco, United States, United States | 2011 |
Ventyx Biosciences
|
Therapeutics for autoimmune diseases are developed by the company. | Encinitas, United States, United States | 2018 |
Ascendis Pharma
|
Long-acting prodrug therapies are developed for endocrine and rare diseases. | Hellerup, Denmark, Denmark | 2007 |
MorphoSys
|
Therapeutic antibodies for cancer and other diseases are developed. | Planegg, Germany, Germany | 1992 |
Incyte
|
Small molecules are developed for cancer and skin disease treatments. | Wilmington, United States, United States | 1991 |
ALX Oncology
|
ALX Oncology is focused on advancing cancer treatment therapies. | Burlingame, United States, United States | 2015 |
Business Activity of Zumutor Biologics Private Limited
Zumutor Biologics Private Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | ********* |
Auditor Details of Zumutor Biologics Private Limited
Zumutor Biologics Private Limited is audited by T SRIRAM MEHTA & TADIMALLA for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| T SRIRAM MEHTA & TADIMALLA | blur-value | blur-value | blur-value |
Board of Directors of Zumutor Biologics Private Limited
Zumutor Biologics Private Limited is currently managed by 4 directors, with 6 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Ashwin Raguraman
Also directs:
India Innovation Capital Management Llp, India Innovation Advisors Llp, Tif Advisors Llp and 5 more
|
Nominee Director | 26 Aug 2021 | 4 Years 10 Months | Current |
|
Maloy Ghosh
Also directs:
Agnicel Healthcare Private Limited
|
Whole-Time Director | 01 Oct 2016 | 9 Years 9 Months | Current |
| Kavitha Iyer Rodrigues | Ceo | 01 Oct 2016 | 9 Years 9 Months | Current |
Financials of Zumutor Biologics Private Limited FY 2025 filings available
Zumutor Biologics Private Limited reported revenue of ₹4.63 Cr (down 64% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Zumutor Biologics Private Limited
As of FY 2024, Zumutor Biologics Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings Zumutor Biologics Private Limited
Zumutor Biologics Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Zumutor Biologics Private Limited
Zumutor Biologics Private Limited has a workforce of 23 employees as of Apr 08, 2024.
Employee Count & EPFO Data of Zumutor Biologics Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Zumutor Biologics Private Limited
GSTIN & GST Filing Data of Zumutor Biologics Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Zumutor Biologics Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Zumutor Biologics Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Zumutor Biologics Private Limited
MSME Payment Delays by Zumutor Biologics Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Zumutor Biologics Private Limited
Subsidiaries & Group Companies of Zumutor Biologics Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Zumutor Biologics Private Limited with ownership details.
MCA Filings & Documents of Zumutor Biologics Private Limited
MCA Filings & Documents of Zumutor Biologics Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Zumutor Biologics Private Limited
Recent News on Zumutor Biologics Private Limited
Frequently Asked Questions about Zumutor Biologics Private Limited
Zumutor Biologics Private Limited is an active foreign private limited company in the life sciences sector based in Bangalore, Karnataka, India. It was incorporated on 31 July 2015 (11+ years old) and is registered under CIN U73200KA2015FTC081944. The company has 23 employees.
Zumutor Biologics Private Limited reported revenue of ₹4.63 Cr for FY 2025 (down 64.00% YoY).
The current directors of Zumutor Biologics Private Limited are:
- Ashwin Raguraman
- Maloy Ghosh
- Kavitha Iyer Rodrigues
- Anirban Bhattacharya
The primary industry of Zumutor Biologics Private Limited is life sciences. The company specifically operates in biotechnology. The company is currently active in this sector.
Yes, Zumutor Biologics Private Limited is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Zumutor Biologics Private Limited can be reached at the registered office: Prasad Enclave # 118119 Ground Floor Yeswantpur Ind Suburb Ii Stage 5Th Mn, Yeswantpur, Bangalore, Karnataka, India – 560022, or through the website zumutor.com.